無料セミナー : 2018年11月27日『オンコロジーにおける遺伝子治療・CAR-T細胞療法』 DelveInsight Business Research LLP共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌免疫療法の世界市場:種類 (モノクローナル抗体 (非修飾、結合)、癌ワクチン、免疫チェックポイント阻害剤 (PD-1、PD-L1、CTLA-4))・用途別 (肺癌、黒色腫、リンパ腫、白血病)

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022

発行 RNCOS E-Services Pvt. Ltd. 商品コード 423698
出版日 ページ情報 英文 230 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.36円で換算しております。
Back to Top
癌免疫療法の世界市場:種類 (モノクローナル抗体 (非修飾、結合)、癌ワクチン、免疫チェックポイント阻害剤 (PD-1、PD-L1、CTLA-4))・用途別 (肺癌、黒色腫、リンパ腫、白血病) Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022
出版日: 2018年08月14日 ページ情報: 英文 230 Pages
概要

当レポートでは、世界の癌免疫療法の市場について分析し、疾患の概要や主な治療オプション、全体的な市場規模の動向見通し (今後5〜10年間分)、製品クラス別・症状別・地域別の詳細動向、主なパイプライン製品 (治験中の製品) の概要、企業間競争・資本取引の動き、主要企業のプロファイル・市場シェアなどを調査しております。

第1章 アナリストの分析

第2章 分析手法

第3章 癌免疫療法:概要

第4章 市場の促進要因と課題

  • 促進要因
  • 課題
  • 市場機会

第5章 世界の癌免疫療法市場の将来展望

第6章 世界の癌免疫療法市場:製品クラス別

  • モノクローナル抗体 (mAb)
    • 非修飾 (Naked) モノクローナル抗体
    • コンジュゲート (結合) モノクローナル抗体
    • 二重特異性モノクローナル抗体
    • その他
  • 治療ワクチン
    • Provenge
    • Pediarix/Infanrix
  • 免疫チェックポイント阻害剤
    • CTLA-4阻害剤 (Cytotoxic T-Lymphocyte-Associated Protein-4)
    • PD-1/PD-L1阻害剤 (Programmed Death 1/Programmed Death Ligand 1)
  • その他

第7章 世界の癌免疫療法市場:主な症状別

  • 頭頸部癌
  • 肺癌
  • 黒色腫 (メラノーマ)
  • リンパ腫
  • 白血病
  • その他

第8章 世界の癌免疫療法市場:地域別

  • 北米
  • 欧州
  • アジア太平洋地域

第9章 市場の傾向と発展

第10章 癌免疫療法業界における戦略的協力・提携の動き

第11章 癌免疫療法のパイプライン製品の分析

第12章 競争環境

  • 主要企業の市場シェア

第13章 主要企業の分析

  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Amgen Inc.
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Novartis
  • AstraZeneca Plc
  • Pfizer Inc
  • Eli Lilly and Company
目次

Immuno-oncology is a unique approach that uses the body's immune system to fight cancer. These therapies activate an individual's immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types. The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.

According to the report "Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022", the global immuno-oncology market is anticipated to cross US$ 100 Billion by 2022. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.

The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).

The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2016, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.

On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Immuno-Oncology: Overview

4. Market Dynamic

  • 4.1. Drivers
    • 4.1.1. Increasing Cancer Incidences
    • 4.1.2. Immune Checkpoint Inhibitors Sales Driving the Market Growth
    • 4.1.3. Growing Geriatric Population
    • 4.1.4. High Healthcare Spending in Developed Economies
    • 4.1.5. Strong Pipeline
    • 4.1.6. Increasing Efficacy in a Wide Variety of Indications
    • 4.1.7. urgeoning Approval and Uptake of Immuno-Oncology Products
  • 4.2. Challenges
    • 4.2.1. Patent Expiry of Top-Selling Drugs
    • 4.2.2. Increasing Number of Side-Effects Post Immunotherapy Treatment
    • 4.2.3. Sky-High Development Costs of Cancer Immunotherapies
    • 4.2.4. High Cost of Treatment
    • 4.2.5. Lack of Awarenes
  • 4.3. Opportunities
    • 4.3.1. Opdivo and Keytruda Presents Significant Growth Opportunit
    • 4.3.2. Combination Therapies Could Lead to Substantial Increases in Survival
    • 4.3.3. CAR-T Therapies: The Future of Cancer Care
    • 4.3.4. Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immuno-Oncology Market Outlook 2022

6. Global Immuno-Oncology Market, by Product Class

  • 6.1. Monoclonal Antibodies (mAbs)
    • 6.1.1. Naked Monoclonal Antibodies
      • 6.1.1.1. Rituxan (Rituximab)
      • 6.1.1.2. Avastin (Bevacizumab)
      • 6.1.1.3. Herceptin (Trastuzumab)
    • 6.1.2. Conjugated Monoclonal Antibodies
      • 6.1.2.1. ADCETRIS (Brentuximab vedotin)
      • 6.1.2.2. Kadcyla (Ado-trastuzumab emtansine/TDM-1)
    • 6.1.3. Bispecific Monoclonal Antibodies
      • 6.1.3.1. Blincyto (Blinatumomab)
    • 6.1.4. Others
  • 6.2. Therapeutic Vaccines
    • 6.2.1. Provenge
  • 6.3. Immune Checkpoint Inhibitors
    • 6.3.1. CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
      • 6.3.1.1. Yervoy (Ipilimumab)
    • 6.3.2. PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
      • 6.3.2.1. Opdivo (Nivolumab)
      • 6.3.2.2. Keytruda (Pembrolizumab)
  • 6.4. Others

7. Global Immuno-Oncology Market, By Major Indications

  • 7.1. Head & Neck Cancer
  • 7.2. Lung Cancer
  • 7.3. Melanoma
  • 7.4. Lymphoma
  • 7.5. Leukemia
  • 7.6. Others 118

8. Global Immuno-Oncology Market, By Geography

  • 8.1. North America
  • 8.2. Europe
  • 8.3. Asia-Pacific

9. Trends & Developments

  • 9.1. Lucrative Investment Trend
  • 9.2. Emergence of Targeted and Combination Therapies
  • 9.3. NSCLC & Melanoma Showing Greatest Contributions to the IO Market
  • 9.4. Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry

11. Pipeline Analysis of Immuno-Oncology

12. Competitive Landscape

  • 12.1. Share of Major Players

13. Key Players Analysis

  • 13.1. F. Hoffmann-La Roche AG
  • 13.2. Celgene Corporation
  • 13.3. Bristol-Myers Squibb
  • 13.4. Merck & Co., Inc.
  • 13.5. Novartis
  • 13.6. AstraZeneca Plc
  • 13.7. Pfizer Inc
  • 13.8. Eli Lilly and Company
  • 13.9. Johnson & Johnson
  • 13.10. Amgen Inc.

List of Figures:

  • Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
  • Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
  • Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
  • Figure 4-4: Expected Combination Regimen Launches in Oncology
  • Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2016
  • Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2022
  • Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2016-2022
  • Figure 6-4: Global - Rituxan Market (Billion US$), 2012-2016
  • Figure 6-5: Global - Avastin Market (Billion US$), 2012-2016
  • Figure 6-6: Global - Herceptin Market (Billion US$), 2012-2016
  • Figure 6-7: Global - ADCETRIS Market (Million US$), 2012-2016
  • Figure 6-8: Global - Kadcyla Market (Million US$), 2013-2016
  • Figure 6-9: Global - Blincyto Market (Million US$), 2014-2016
  • Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), 2016-2022
  • Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Billion US$), 2016-2022
  • Figure 6-12: Global - Provenge Market (Million US$), 2012-2016
  • Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
  • Figure 6-14: Global - Yervoy Market (Million US$), 2012-2016
  • Figure 6-15: Global - Opdivo Market (Million US$), 2014-2016
  • Figure 6-16: Global - Keytruda Market (Million US$), 2014-2016
  • Figure 6-17: Global - Others Market (Billion US$), 2016-2022
  • Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2016
  • Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2022
  • Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2016-2022
  • Figure 7-4: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-5: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-6: Global - Lung Cancer Market (Billion US$), 2016-2022
  • Figure 7-7: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-8: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-9: Global - Melanoma Market (Billion US$), 2016-2022
  • Figure 7-10: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-11: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-12: Global - Lymphoma Market (Billion US$), 2016-2022
  • Figure 7-13: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-14: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-15: Global - Leukemia Market (Billion US$), 2016-2022
  • Figure 7-16: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-17: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-18: Global - Other Cancer Market (Billion US$), 2016-2022
  • Figure 7-19: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-20: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 8-1: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2016
  • Figure 8-2: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2022
  • Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 9-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016
  • Figure 9-2: Major Investors in Immuno-Oncology Market (2015-2016)
  • Figure 9-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
  • Figure 11-1: Global - Immuno-Oncology Pipeline Analysis by Product Type (%), 2016
  • Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2016
  • Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2015
  • Figure 13-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016
  • Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016
  • Figure 13-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016
  • Figure 13-4: Celgene Corporation - Sales by Products (%), 2016
  • Figure 13-5: Bristol Myers Squibb - Revenue by Business Segments (%), 2016
  • Figure 13-6: Bristol Myers Squibb - Revenue by Geography (%), 2016
  • Figure 13-7: Merck & Co., Inc. - Revenue by Business Segments (%), 2016
  • Figure 13-8: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016
  • Figure 13-9: Merck & Co., Inc. - Revenue by Geography (%), 2016
  • Figure 13-10: Novartis - Sales by Business Segments (%), 2016
  • Figure 13-11: Novartis - Innovative Medicines Division Sales by Segments (%), 2016
  • Figure 13-12: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016
  • Figure 13-13: Novartis - Sales by Geography (%), 2016
  • Figure 13-14: AstraZeneca Plc - Revenue by Business Segments (%), 2016
  • Figure 13-15: AstraZeneca Plc - Revenue by Geography (%), 2016
  • Figure 13-16: Pfizer Inc - Revenue by Business Segments (%), 2016
  • Figure 13-17: Pfizer Inc - Revenue by Geography (%), 2016
  • Figure 13-18: Eli Lilly and Company - Revenue by Business Segments (%), 2016
  • Figure 13-19: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segments (%), 2016
  • Figure 13-20: Eli Lilly and Company - Revenue by Geography (%), 2016
  • Figure 13-21: Johnson & Johnson - Sales by Business Segments (%), 2016
  • Figure 13-22: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016
  • Figure 13-23: Johnson & Johnson - Sales by Geography (%), 2016
  • Figure 13-24: Amgen Inc. - Sales by Product (%), 2016
  • Figure 13-25: Amgen Inc. - Sales by Geography (%), 2016

List of Tables:

  • Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
  • Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
  • Table 6-1: Ongoing Trials for Rituxan
  • Table 6-2: Ongoing Trials for Avastin
  • Table 6-3: Ongoing Trials for Herceptin
  • Table 6-4: Ongoing Trials for ADCETRIS
  • Table 6-5: Ongoing Trials for Kadcyla
  • Table 6-6: Ongoing Trials for Blincyto
  • Table 6-7: Ongoing Trials for Other Monoclonal Antibodies
  • Table 6-8: Ongoing Trials for Provenge
  • Table 6-9: Ongoing Trials for Yervoy
  • Table 6-10: Ongoing Trials for Opdivo
  • Table 6-11: Ongoing Trials for Keytruda
  • Table 6-12: Ongoing Trials for Other Immuno-Oncology Products
  • Table 7-1: Global - Oncology Incidence by Geography ('000), 2015 & 2020
  • Table 9-1: Immuno-Oncology Companies that Received Venture Capital Investments
  • Table 9-2: Selected Immuno-Oncology and/or Targeted Therapy Combinations
  • Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
  • Table 11-1: Active Immuno-Oncology Programs
  • Table 11-2: Global - Immuno-Oncology Product Pipeline
  • Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016
  • Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products
  • Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline
  • Table 13-4: Celgene Corporation - Key Financials (Million US$), 2014-2016
  • Table 13-5: Celgene Corporation - Commercialized Immuno-Oncology Products
  • Table 13-6: Celgene Corporation - Product Pipeline
  • Table 13-7: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016
  • Table 13-8: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
  • Table 13-9: Bristol Myers Squibb - Product Pipeline
  • Table 13-10: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016
  • Table 13-11: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
  • Table 13-12: Merck & Co., Inc. - Product Pipeline
  • Table 13-13: Novartis - Key Financials (Billion US$), 2014-2016
  • Table 13-14: Novartis - Commercialized Immuno-Oncology Products
  • Table 13-15: Novartis - Product Pipeline
  • Table 13-16: AstraZeneca Plc - Key Financials (Million US$), 2014-2016
  • Table 13-17: AstraZeneca Plc - Commercialized Immuno-Oncology Products
  • Table 13-18: AstraZeneca Plc - Product Pipeline
  • Table 13-19: Pfizer Inc - Key Financials (Billion US$), 2014-2016
  • Table 13-20: Pfizer Inc - Commercialized Immuno-Oncology Products
  • Table 13-21: Pfizer Inc - Product Pipeline
  • Table 13-22: Eli Lilly and Company - Key Financials (Million US$), 2014-2016
  • Table 13-23: Eli Lilly and Company - Commercialized Immuno-Oncology Products
  • Table 13-24: Eli Lilly and Company - Product Pipeline
  • Table 13-25: Johnson & Johnson - Key Financials (Billion US$), 2014-2016
  • Table 13-26: Johnson & Johnson - Commercialized Immuno-Oncology Products
  • Table 13-27: Johnson & Johnson - Product Pipeline
  • Table 13-28: Amgen Inc. - Key Financials (Billion US$), 2014-2016
  • Table 13-29: Amgen Inc. - Commercialized Immuno-Oncology Products
  • Table 13-30: Amgen Inc. - Product Pipeline
Back to Top